Alan Landay to Anti-HIV Agents
This is a "connection" page, showing publications Alan Landay has written about Anti-HIV Agents.
Connection Strength
6.447
-
Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014 Oct 15; 210(8):1248-59.
Score: 0.449
-
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010 Jun 15; 201(12):1796-805.
Score: 0.343
-
Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009 Oct 15; 200(8):1212-5.
Score: 0.327
-
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis. 2007 Mar 01; 44(5):749-54.
Score: 0.271
-
Antigen-presenting cells in HIV pathogenesis and therapy: summary of the October 17-18, 2002, Think Tank meeting. Clin Immunol. 2002 Jun; 103(3 Pt 1):243-8.
Score: 0.196
-
HIV and Aging in the Era of ART and COVID-19: Symposium Overview. J Acquir Immune Defic Syndr. 2022 02 01; 89(Suppl 1):S3-S9.
Score: 0.192
-
Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS. 2000 May 05; 14(7):761-70.
Score: 0.170
-
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000 Jan; 181(1):358-63.
Score: 0.166
-
Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment. J Neurovirol. 2020 02; 26(1):107-113.
Score: 0.162
-
Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor. J Acquir Immune Defic Syndr. 2019 08 15; 81(5):585-593.
Score: 0.162
-
Vitamin D does not modulate immune-mediated bone loss during ART initiation. Antivir Ther. 2019; 24(5):355-362.
Score: 0.155
-
Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS. 1998 Jul 30; 12(11):F123-9.
Score: 0.151
-
Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy. J Leukoc Biol. 2018 09; 104(3):461-471.
Score: 0.147
-
Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. DATRI 003 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res Hum Retroviruses. 1998 Mar 20; 14(5):445-51.
Score: 0.147
-
Immune restoration following treatment. Abstract and Commentary. JAMA. 1997 Nov 12; 278(18):1538.
Score: 0.143
-
Immunological effects of antiretroviral and immune therapies for HIV. AIDS. 1997; 11 Suppl A:S149-55.
Score: 0.135
-
Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS. 2016 08 24; 30(13):2091-7.
Score: 0.132
-
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS. 2016 Mar 27; 30(6):869-78.
Score: 0.128
-
The Association of Human Cytomegalovirus with Biomarkers of Inflammation and Immune Activation in HIV-1-Infected Women. AIDS Res Hum Retroviruses. 2016 Feb; 32(2):134-43.
Score: 0.124
-
Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study. Clin Infect Dis. 2015 Oct 01; 61(7):1179-88.
Score: 0.121
-
Older age is associated with peripheral blood expansion of na?ve B cells in HIV-infected subjects on antiretroviral therapy. PLoS One. 2014; 9(9):e107064.
Score: 0.115
-
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr. 2014 Aug 01; 66(4):399-406.
Score: 0.114
-
Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction. AIDS. 2013 Jun 19; 27(10):1563-71.
Score: 0.106
-
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4? T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis. 2012 Aug 15; 206(4):534-42.
Score: 0.099
-
Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS. 2010 Jul 17; 24(11):1657-65.
Score: 0.086
-
Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses. 2010 Jun; 26(6):635-43.
Score: 0.086
-
Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother. 2010 Feb; 54(2):871-81.
Score: 0.083
-
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009 Apr 15; 199(8):1177-85.
Score: 0.079
-
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. AIDS. 2009 Mar 13; 23(5):605-10.
Score: 0.079
-
Chemokine analogues show suitable stability for development as microbicides. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):472-6.
Score: 0.077
-
Characterization of quantitative and functional innate immune parameters in HIV-1-infected Colombian children receiving stable highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):348-57.
Score: 0.077
-
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Arch Intern Med. 2007 Mar 26; 167(6):597-605.
Score: 0.069
-
A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther. 2007; 12(4):531-41.
Score: 0.067
-
Innate immune defenses in HIV-1 infection: prospects for a novel immune therapy. Expert Rev Anti Infect Ther. 2006 Oct; 4(5):767-80.
Score: 0.066
-
Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis. 2006 May 01; 193(9):1202-10.
Score: 0.064
-
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19; 366(9485):549-55.
Score: 0.061
-
HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course. J Acquir Immune Defic Syndr. 2003 Dec 15; 34(5):491-6.
Score: 0.055
-
Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis. 2003 Feb 01; 187(3):375-84.
Score: 0.051
-
A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS. 2002 May 24; 16(8):1147-54.
Score: 0.049
-
Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens. J Acquir Immune Defic Syndr. 2002 Apr 15; 29(5):544-5.
Score: 0.049
-
Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy. AIDS. 2021 12 01; 35(15):2489-2495.
Score: 0.047
-
Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001 Sep 01; 17(13):1231-40.
Score: 0.047
-
Detection of T cell receptor circles (TRECs) as biomarkers for de novo T cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA). J Immunol Methods. 2000 Apr 03; 237(1-2):187-97.
Score: 0.042
-
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. J Infect Dis. 2000 Feb; 181(2):491-7.
Score: 0.042
-
Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis. 2000 Jan; 181(1):141-7.
Score: 0.042
-
Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs. J Acquir Immune Defic Syndr. 2019 12 15; 82(5):503-513.
Score: 0.041
-
Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons. AIDS Res Hum Retroviruses. 1999 Dec 10; 15(18):1713-5.
Score: 0.041
-
HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication. AIDS. 1999 Jul 09; 13(10):1177-85.
Score: 0.040
-
Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. Clin Immunol. 1999 Jul; 92(1):14-24.
Score: 0.040
-
Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers. Infect Control Hosp Epidemiol. 1999 Jun; 20(6):428-30.
Score: 0.040
-
Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points. J Infect Dis. 1999 Apr; 179(4):799-807.
Score: 0.039
-
Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures. JAMA. 1999 Mar 24-31; 281(12):1085-6.
Score: 0.039
-
Monitoring HIV-1 treatment in immune-cell subsets with ultrasensitive fluorescence-in-situ hybridisation. Lancet. 1999 Jan 16; 353(9148):211-2.
Score: 0.039
-
Higher Anti-Cytomegalovirus Immunoglobulin G Concentrations Are Associated With Worse Neurocognitive Performance During Suppressive Antiretroviral Therapy. Clin Infect Dis. 2018 08 16; 67(5):770-777.
Score: 0.038
-
In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest. 1998 Jul 01; 102(1):79-87.
Score: 0.037
-
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul; 178(1):70-9.
Score: 0.037
-
Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA. 1998 Jul 01; 280(1):72-7.
Score: 0.037
-
Lymphocyte phenotyping in infants: maturation of lymphocyte subpopulations and the effects of HIV infection. Clin Immunol Immunopathol. 1997 Dec; 85(3):273-81.
Score: 0.036
-
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy. J Infect Dis. 2017 10 17; 216(7):813-818.
Score: 0.036
-
Higher Body Mass Index Is Associated With Greater Proportions of Effector CD8+ T Cells Expressing CD57 in Women Living With HIV. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):e132-e141.
Score: 0.035
-
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Na?ve to Antiretroviral Therapy: A Pilot Randomized Trial. PLoS Pathog. 2016 Jan; 12(1):e1005381.
Score: 0.032
-
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012 Jul 01; 60 Suppl 1:S1-18.
Score: 0.025
-
CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies. J Infect Dis. 2012 Jun; 205(11):1730-8.
Score: 0.024
-
HIV infection and aging of the innate immune system. Sex Health. 2011 Dec; 8(4):453-64.
Score: 0.024
-
Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181. Clin Vaccine Immunol. 2010 Sep; 17(9):1452-9.
Score: 0.022
-
Enhanced antibody responses elicited by a CpG adjuvant do not improve the protective effect of an aldrithiol-2-inactivated simian immunodeficiency virus therapeutic AIDS vaccine. Clin Vaccine Immunol. 2009 Apr; 16(4):499-505.
Score: 0.020
-
Dysfunctional natural killer cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on antiretroviral therapy. AIDS. 2007 Nov 12; 21(17):2363-5.
Score: 0.018
-
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. AIDS. 2007 Jan 30; 21(3):293-305.
Score: 0.017
-
Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels. J Infect Dis. 2007 Mar 01; 195(5):734-8.
Score: 0.017
-
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006 Dec; 12(12):1365-71.
Score: 0.017
-
Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis. 2004 Dec 01; 190(11):1970-8.
Score: 0.015
-
Role of Baseline pol Genotype in HIV-1 Fitness Evolution. J Acquir Immune Defic Syndr. 2003 Aug 01; 33(4):448-60.
Score: 0.013
-
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 Aug 15; 37(4):551-8.
Score: 0.013
-
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis. 2003 Jan 15; 187(2):320-5.
Score: 0.013
-
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS. 2000 Jan 07; 14(1):11-21.
Score: 0.010
-
Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS. 1999 May 28; 13(8):919-25.
Score: 0.010
-
Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis. 1997 Mar; 175(3):567-75.
Score: 0.009